文献速递类风湿关节炎

迪诺塞麦抑制类风湿关节炎关节破坏进展的优选亚组分析

Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction.
PubMed 文献 · RMD Open · 2020-01-01

该研究汇总DRIVE和DESIRABLE两项试验的909例类风湿关节炎患者数据,发现迪诺塞麦60 mg每6个月或每3个月均可显著延缓mTSS进展,且效果主要来自骨侵蚀评分改善而非关节间隙狭窄。抗CCP抗体阳性、糖皮质激素使用和基线骨侵蚀评分与疗效存在显著交互作用,抗CCP抗体阳性者获益尤为明显。

要点

  • 迪诺塞麦可延缓RA影像学关节破坏进展,主要减少骨侵蚀而非关节间隙狭窄。
  • 抗CCP抗体阳性患者使用迪诺塞麦的获益尤为显著。
  • 糖皮质激素使用和基线骨侵蚀评分不影响迪诺塞麦对mTSS的总体疗效。

核心结论

  • 迪诺塞麦能广泛减缓具有影像学损伤风险因素的RA患者关节破坏进展,尤其抗CCP抗体阳性者获益更明显。

研究设计与样本

  • 汇总12个月双盲安慰剂对照DRIVE(II期)和DESIRABLE(III期)研究患者数据,共纳入909例RA患者。
  • 患者随机接受迪诺塞麦60 mg每6个月、每3个月或安慰剂,以mTSS、骨侵蚀评分和关节间隙狭窄评分评估疗效。

主要发现

  • 12个月时mTSS恶化均值(SD)在每6个月组为0.88(3.30)(p=0.0024)、每3个月组为0.66(2.16)(p=0.0002),均低于安慰剂组1.50(3.73)。
  • 骨侵蚀评分变化在每6个月组为0.44(1.89)(p=0.0006)、每3个月组为0.20(0.86)(p<0.0001),安慰剂组为0.98(2.54);关节间隙狭窄评分未见显著效果。
  • 抗CCP抗体、糖皮质激素使用和基线骨侵蚀评分显示显著交互作用,迪诺塞麦在抗CCP抗体阳性患者中尤其有效(p<0.05)。
  • 无论是否使用糖皮质激素及基线骨侵蚀评分如何,各迪诺塞麦剂量组均观察到mTSS变化优于安慰剂。

关键数值与推荐

  • 抗CCP抗体阳性患者使用迪诺塞麦后mTSS变化优于安慰剂(p<0.05)。

临床怎么用

  • 对于抗CCP抗体阳性的RA患者,可考虑使用迪诺塞麦以延缓关节破坏进展。
  • 迪诺塞麦的关节保护作用主要体现在抑制骨侵蚀,对关节间隙狭窄无明显影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To clarify which rheumatoid arthritis (RA) patients benefit most from the anti-receptor activator of nuclear factor-κB ligand antibody denosumab to reduce the progression of joint destruction. METHODS: We pooled patient data from the 12-month, double-blind, placebo-controlled DRIVE (phase II) and DESIRABLE (phase III) studies. In DRIVE, concomitant treatment was limited to methotrexate, salazosulfapyridine and bucillamine. In DESIRABLE, patients could receive any disease-modifying antirheumatic drug. RA patients were randomised to denosumab 60 mg every 6 months (Q6M), every 3 months (Q3M) or placebo. Efficacy was assessed by van der Heijde-modified total Sharp score (mTSS), bone erosion score (ES) and joint space narrowing score (JSNS). Change in mTSS was assessed in subgroups stratified by risk factors for radiographic damage if the interaction factor was significant. RESULTS: The pooled analysis included 909 patients. Denosumab reduced worsening of mTSS (mean (SD)) at 12 months in the Q6M (0.88 (3.30), p=0.0024) and Q3M (0.66 (2.16), p=0.0002) groups versus placebo (1.50 (3.73)). This reduction in mTSS progression was due to the change in ES (Q6M, 0.44 (1.89), p=0.0006; Q3M, 0.20 (0.86), p<0.0001) versus placebo (0.98 (2.54)); no effect was observed on JSNS. Anti-cyclic citrullinated peptide (CCP) antibodies, glucocorticoid use and baseline ES showed a significant interaction. Denosumab was particularly effective in patients who were anti-CCP antibody positive (p<0.05). Changes in mTSS versus placebo were observed in all denosumab dose groups, regardless of glucocorticoid use and baseline ES. CONCLUSIONS: Denosumab broadly reduced the progression of joint destruction in RA patients with risk factors for radiographic damage such as especially anti-CCP antibody positivity.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Tanaka Y, Soen S, Ishiguro N, et al. Identifying the preferable rheumatoid arthritis subgroups for intervention with the anti-RANKL antibody denosumab to reduce progression of joint destruction. RMD Open. 2020. PMID: 32732353. doi:10.1136/rmdopen-2020-001249

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。